Business
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 /Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" ...
About this update from Telomir Pharmaceuticals, Inc.
[{"type":"text","content":"No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.","length":145,"tagName":"p"},{"type":"text","content":"MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir).","length":498,"tagName":"p"},{"type":"text","content":"The studies were conducted as part of the Company's ongoing IND-enabling program and evaluated cardiovascular, respiratory, phototoxicity, and repeat-dose toxicology using a combination of in vitro systems and in vivo rat and dog models. While final quality assurance (QA) review of the study reports is ongoing, the Company does not expect the overall conclusions to change.","length":379,"tagName":"p"},{"type":"text","content":"Key Safety Findings","length":19,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Overall Safety:Telomir-1 was well tolerated across all completed GLP safety studies, with no treatment-related adverse or dose-limiting toxicities observed.","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Cardiovascular Safety:In non-rodent studies, including in dogs, no test-article-related changes in blood pressure, heart rate, electrocardiogram (ECG) parameters, or body temperature were observed following oral administration. In addition, no concerning cardiac safety signals were identified in a validated GLP assay commonly used to assess arrhythmia risk.","length":360,"tagName":"p"}]},{"val":[{"type":"text","content":"Repeated-Dose Toxicology:Repeated oral administration in both rats and dogs were well tolerated. Observed findings were limited, reversible, and considered non-adverse, with no serious toxicological findings identified.","length":220,"tagName":"p"}]},{"val":[{"type":"text","content":"Respiratory Safety:No clinically meaningful effects on respiratory function were observed.","length":91,"tagName":"p"}]},{"val":[{"type":"text...